oral tirzepatide eli lilly weight loss drug data released Lilly says weight loss drug

Tirzepatide is a dual GIP and GLP-1 receptor agonist with no known direct effect on renal potassium handling or aldosterone activity

This physiological change can lead to a sharp uptick in food cravings, larger portion sizes, and more frequent eating

The average retail price of Ozempic ranges between $1,000 and $1,300 per month without medications

These provide little nutritional value and can worsen blood sugar fluctuations

Available under different brand names like Wegovy and Ozempic, semaglutide is formulated to help with both weight management and type 2 diabetes

Assuming Eli Lilly follows a similar timeline to tirzepatide, the earliest possible FDA approval for retatrutide would likely occur in late 2027 or 2028, depending on Phase 3 trial results and regulatory review timelines